Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study

Completed

• Conditions: Gastroesophageal Reflux Disease

• Registration Number: NCT00963144
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2009-08-12
• Study First Submitted QC: 2009-08-20
• Study First Posted: 2009-08-21
• Primary Completion: 2009-11
• Study Completion: 2009-11
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-20
• Last Update Posted: 2010-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Patients of either gender aged between 18-79 years of age
• Patients must be having symptoms of gastroesophageal reflux disease

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the applicability and utility of Gerd Q in the diagnosis of GERD and assessment of treatment response	The applicability and utility of the Gerd Questionnaire will be done on 2 vists- Day 1 and Day 30

Secondary Outcome Measures

Name	Time	Method
To assess and monitor the treatment response of patients diagnosed with GERD	The monitoring and assessment of treatment response using the Gerd Questionnaire will be done on 2 vists-Day 1 and Day 30

Trial Locations

Locations (1)

Research Site; 🇲🇾 Selangor, Malaysia